Plain-English translation of NCT05581030 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing , a new medication, when combined with a standard multi-drug chemotherapy regimen called Hyper-CVAD for young adults with newly diagnosed acute lymphoblastic leukemia (ALL). Researchers want to see if adding this medication to the chemotherapy is safe, well-tolerated, and helpful. This is an early-stage study with a small group of participants.
ALL is a serious blood cancer, and while standard chemotherapy helps many patients, doctors are always looking for ways to improve outcomes and reduce side effects. This medication may help enhance the effectiveness of existing chemotherapy treatments.
You likely qualify if…
You likely don't qualify if…
Participants will receive the new medication () as an infusion over 1 hour, given alongside each cycle of their chemotherapy treatment. Treatment continues through multiple cycles of chemotherapy, and patients who respond well may have their chemotherapy doses adjusted. Some participants (those with a specific type of ALL called CD20+) will also receive an additional medication called once per cycle. You'll need to attend regular clinic visits for treatment and monitoring, and your doctor will watch closely for side effects and how well the treatment is working.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Collaborators
Servier
Enrollment target
~7 participants
Started
May 2023
Primary completion
October 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 50 Years
Last updated on clinicaltrials.gov in March 2026.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.